A phase i first-in-human study of nesvacumab (REGN910), a fully human anti-angiopoietin-2 (Ang2) monoclonal antibody, in patients with advanced solid tumors

Clinical Cancer Research

Volumn 22, Issue 6, 2016, Pages 1348-1355

  Papadopoulos, Kyriakos P ^a   Kelley, Robin Kate ^b   Tolcher, Anthony W ^a   Abdul Razak, Albiruni R ^c   Van Loon, Katherine ^b   Patnaik, Amita ^a   Bedard, Philippe L ^c   Alfaro, Ariceli A ^b   Beeram, Muralidhar ^a   Adriaens, Lieve ^d   Brownstein, Carrie M ^d   Lowy, Israel ^d   Kostic, Ana ^d   Trail, Pamela A ^d   Gao, Bo ^d   DiCioccio, A Thomas ^d   Siu, Lillian L ^c  

^a South Texas Accelerated Research Therapeutics (START)   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c PRINCESS MARGARET HOSPITAL   (Canada)

^d REGENERON PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; NESVACUMAB; ANGIOPOIETIN 2; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; MONOCLONAL ANTIBODY;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADRENAL CORTEX CARCINOMA; ADULT; AGED; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANADA; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL ARTICLE; COGNITIVE DEFECT; DECREASED APPETITE; DIARRHEA; DOSE LIMITING TOXICITY; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TOXICITY; FATIGUE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOGENICITY; INFUSION RELATED REACTION; LIVER CELL CARCINOMA; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL (TOPIC); PLEURA EFFUSION; PRIORITY JOURNAL; RETINA DETACHMENT; SOLID TUMOR; TREATMENT DURATION; TUMOR BIOPSY; UNITED STATES; VERY ELDERLY; ANTAGONISTS AND INHIBITORS; CANCER STAGING; CLINICAL TRIAL; DOSE RESPONSE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; PATHOLOGY; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANGIOPOIETIN-2; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BIOMARKERS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84962232352     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-1221     Document Type: Article

References (37)

1. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350: 2335-42.
2. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-50.
3. Van Cutsem E, Tabernero J, Lakomy R, Prenen H, Prausova J, Macarulla T, et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol 2012;30:3499-506.
4. Garon EB, Ciuleanu TE, Arrieta O, Prabhash K, Syrigos KN, Goksel T, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet 2014; 384:665-73.
5. Davis S, Aldrich TH, Jones PF, Acheson A, Compton DL, Jain V, et al. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell 1996;87:1161-9.
6. Maisonpierre PC, Suri C, Jones PF, Bartunkova S,Wiegand SJ, Radziejewski C, et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 1997;277:55-60.
7. Augustin HG, Koh GY, Thurston G, Alitalo K. Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system. Nat Rev Mol Cell Biol 2009;10:165-77.
8. Thurston G, Daly C. The complex role of angiopoietin-2 in the angiopoietin- tie signaling pathway. Cold SpringHarb Perspect Med2012;2:a006550.
9. Suri C, Jones PF, Patan S, Bartunkova S, Maisonpierre PC, Davis S, et al. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 1996;87:1171-80.
10. Thurston G, Rudge JS, Ioffe E, Zhou H, Ross L, Croll SD, et al. Angiopoietin- 1 protects the adult vasculature against plasma leakage. Nat Med 2000;6:460-3.
11. Thurston G, Suri C, Smith K, McClain J, Sato TN, Yancopoulos GD, et al. Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1. Science 1999;286:2511-4.
12. Brown JL, Cao ZA, Pinzon-Ortiz M, Kendrew J, Reimer C, Wen S, et al. A human monoclonal anti-ANG2 antibody leads to broad antitumor activity in combination with VEGF inhibitors and chemotherapy agents in preclinical models. Mol Cancer Ther 2010;9:145-56.
13. Daly C, Eichten A, Castanaro C, Pasnikowski E, Adler A, Lalani AS, et al. Angiopoietin-2 functions as a Tie2 agonist in tumor models, where it limits the effects of VEGF inhibition. Cancer Res 2013; 73:108-18.
14. Falcon BL, Hashizume H, Koumoutsakos P, Chou J, Bready JV, Coxon A, et al. Contrasting actions of selective inhibitors of angiopoietin-1 and angiopoietin-2 on the normalization of tumor blood vessels. Am J Pathol 2009;175:2159-70.
15. Nasarre P, Thomas M, Kruse K, Helfrich I, Wolter V, Deppermann C, et al. Host-derived angiopoietin-2 affects early stages of tumor development and vessel maturation but is dispensable for later stages of tumor growth. Cancer Res 2009;69:1324-33.
16. Oliner J, Min H, Leal J, Yu D, Rao S, You E, et al. Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin- 2. Cancer Cell 2004;6:507-16.
17. Detjen KM, Rieke S, Deters A, Schulz P, Rexin A, Vollmer S, et al. Angiopoietin- 2 promotes disease progression of neuroendocrine tumors. Clin Cancer Res 2010;16:420-9.
18. Helfrich I, Edler L, Sucker A, Thomas M, Christian S, Schadendorf D, et al. Angiopoietin-2 levels are associated with disease progression in metastatic malignant melanoma. Clin Cancer Res 2009;15: 1384-92.
19. Park JH, Park KJ, Kim YS, Sheen SS, Lee KS, Lee HN, et al. Serum angiopoietin-2 as a clinical marker for lung cancer. Chest 2007;132: 200-6.
20. Stratmann A, Risau W, Plate KH. Cell type-specific expression of angiopoietin- 1 and angiopoietin-2 suggests a role in glioblastoma angiogenesis. Am J Pathol 1998;153:1459-66.
21. Tanaka S, Mori M, Sakamoto Y, Makuuchi M, Sugimachi K, Wands JR. Biologic significance of angiopoietin-2 expression in human hepatocellular carcinoma. J Clin Invest 1999;103:341-5.
22. Llovet JM, Pena CE, Lathia CD, Shan M, Meinhardt G, Bruix J, et al. Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma. Clin Cancer Res 2012;18:2290-300.
23. Sallinen H, Heikura T, Koponen J, Kosma VM, Heinonen S, Yla-Herttuala S, et al. Serum angiopoietin-2 and soluble VEGFR-2 levels predictmalignancy of ovarian neoplasm and poor prognosis in epithelial ovarian cancer. BMC Cancer 2014;14:696.
24. Bruix J, Sherman M American Association for the Study of Liver D. Management of hepatocellular carcinoma: an update. Hepatology 2011;53: 1020-2.
25. Herbst RS, Hong D, Chap L, Kurzrock R, Jackson E, Silverman JM, et al. Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors. JClin Oncol 2009;27:3557-65.
26. Dowlati A, Vlahovic G, Natale RB, Rasmussen E, Singh I, Hwang YC, et al. A first-in-human study of AMG 780, an angiopoietin-1 and -2 (ANG1/2) inhibitor, in patients (pts) with advanced solid tumors. J Clin Oncol 2014;32:5s.
27. Genentech. Avastin (Bevacizumab) Package Insert. South San Francisco, CA.
28. Sanofi. Zaltrap (Ziv-aflibercept). Package Insert. Bridgewater, NJ.
29. Satchell SC, Harper SJ, Tooke JE, Kerjaschki D, SaleemMA,Mathieson PW. Human podocytes express angiopoietin 1, a potential regulator of glomerular vascular endothelial growth factor. J Am Soc Nephrol 2002; 13:544-50.
30. Davis B, Dei Cas A, Long DA, White KE, Hayward A, Ku CH, et al. Podocytespecific expression of angiopoietin-2 causes proteinuria and apoptosis of glomerular endothelia. J Am Soc Nephrol 2007;18:2320-9.
31. Woolf AS, Gnudi L, Long DA. Roles of angiopoietins in kidney development and disease. J Am Soc Nephrol 2009;20:239-44.
32. Hinchey J, Chaves C, Appignani B, Breen J, Pao L, Wang A, et al. A reversible posterior leukoencephalopathy syndrome. N Engl J Med 1996;334:494-500.
33. Tlemsani C, Mir O, Boudou-Rouquette P, Huillard O, Maley K, Ropert S, et al. Posterior reversible encephalopathy syndrome induced by anti-VEGF agents. Target Oncol 2011;6:253-8.
34. de Leeuw FE, de Groot JC, Achten E, Oudkerk M, Ramos LM, Heijboer R, et al. Prevalence of cerebral white matter lesions in elderly people: a population based magnetic resonance imaging study. The RotterdamScan Study. J Neurol Neurosurg Psychiatry 2001;70:9-14.
35. Wen W, Sachdev P. The topography of white matter hyperintensities on brain MRI in healthy 60- to 64-year-old individuals. Neuroimage 2004;22:144-54.
36. Wang ES, Fetterly G, Brady W, Tan W, Greene J, Gaudy A, et al. Clinical and biologic effects of the angiopoietin 1/2 neutralizing peptibody, trebananib (AMG 386), in acute myeloid leukemia patients. American Society of Hematology (ASH) 55th Annual Meeting, Orlando, FL (abstract 2701).
37. Papadopoulos KP, Graham DM, Tolcher AW, Razak ARA, Patnaik A, Bedard PL, et al. A phase 1b study of combined angiogenesis blockade with nesvacumab, a selective monoclonal antibody (MAb) to angiopoietin- 2 (Ang2) and ziv-aflibercept in patients with advanced solid malignancies. J Clin Oncol 2014;32:5s.